Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-GD2/anti-CD56 4SCAR-expressing bispecific T cells

A preparation of T lymphocytes that are genetically engineered to express a fourth-generation chimeric antigen receptor (4SCAR) targeting the two tumor-associated antigens (TAAs) disialoganglioside (GD2) and CD56 (neural cell adhesion molecule 1; NCAM-1), with potential immunostimulating and antineoplastic activities. Upon administration, the anti-GD2/anti-CD56 4SCAR-expressing bispecific T cells are directed to and induce selective toxicity in GD2- and CD56-expressing tumor cells. GD2 is overexpressed on the surface of neuroblastoma cells and by other neuroectoderm-derived neoplasms, while it is minimally expressed on normal cells. CD56 is overexpressed on the surface of various types of cancer cells, including small cell lung cancer (SCLC) and other neuroendocrine tumors (NETs).
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-CD56/anti-GD2 4SCAR-expressing bispecific T cells
anti-GD2/anti-NCAM-1 4SCAR-expressing bispecific T cells
anti-GD2/CD56 bispecific 4SCAR-expressing T cells
bi-4SCAR GD2/CD56 T cells
GD2/CD56 bispecific 4SCAR-T cells
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search